Sotalex

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Sotalex

Quick Facts

Property Description
Active Ingredient Sotalol hydrochloride
Form Tablet (Oral form)
Pharmacological Class Non-selective beta-blocker; Class III Antiarrhythmic
Common Use Heart rhythm control
Origin Synthetic compound

Sotalex: Identity, Composition, and Origin

Sotalex is a prescription-only medicine whose therapeutic foundation is the active ingredient, Sotalol hydrochloride. This substance is a synthetic compound that belongs to the methanesulfonanilide class, and the drug is a single active ingredient product. For patient convenience and systemic effect, the medication is formulated for oral administration, primarily supplied as tablets or film-coated tablets.

The compound Sotalol hydrochloride is delivered as a racemic mixture within the dosage form. As an established active substance, its quality and composition are tightly controlled, ensuring a reliable effect. This level of control is clinically recognized for ensuring consistent systemic delivery, which is vital in cardiac therapies.


What Pharmacological Classes Define Sotalol?

Sotalol is uniquely categorized by its dual pharmacological properties: it is classified as both a non-selective beta-adrenergic receptor blocker (Class II) and a Class III antiarrhythmic agent. This combination represents a key differentiating factor from other beta-blockers, positioning Sotalol as a specialized agent in its class.

The general purpose of Sotalol is to provide comprehensive heartbeat stabilization and rate regulation. Sotalol is indicated for documented ventricular arrhythmias. This confirms that Sotalol is a key therapeutic option used by doctors to manage serious rhythm disorders. This dual action is central to its therapeutic application in cardiac rhythm control.

Regulatory References

  1. Sotalol - StatPearls - NIH
  2. FDA Label for Sotalol
  3. FDA Label SOTALOL

What side effects are possible with Sotalex?

Possible Side Effects and Safety Information for Sotalex

Sotalex (sotalol hydrochloride) carries a Boxed Warning due to the risk of life-threatening proarrhythmia, notably Torsade de Pointes (TdP), which is directly related to dose and QTc interval prolongation. To minimize this serious risk, initiation and dose adjustments must be conducted in a setting capable of continuous electrocardiographic (ECG) monitoring and cardiac resuscitation.

Serious and Common Adverse Reactions

Classification Key Adverse Reactions
Serious Torsade de Pointes, sustained ventricular tachycardia, significant QT prolongation, bradycardia, worsening heart failure, hypotension, anaphylaxis.
Most Common Fatigue, dizziness, headache, bradycardia, dyspnea (shortness of breath), asthenia (lack of energy), nausea, and palpitations. These effects are often dose-related.

Safety Limitations and Monitoring

Sotalex is contraindicated in patients with conditions that increase the risk of proarrhythmia, including a baseline QTc interval over 450 ms, significant renal impairment (creatinine clearance <40 mL/min for AFIB/AFL), uncontrolled heart failure, bronchial asthma, or a serum potassium level <4 mEq/L.

  • Electrolyte Balance: Hypokalemia and hypomagnesemia must be corrected before starting therapy as they increase the risk of TdP.
  • Abrupt Cessation: Do not discontinue therapy suddenly, particularly in patients with ischemic heart disease, as this may lead to an acute exacerbation of angina or myocardial infarction.
  • Population-Specific: Beta-blockade may mask symptoms of hypoglycemia in diabetic patients and the clinical signs of hyperthyroidism. Patients with renal impairment require careful dose adjustment to prevent drug accumulation.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory information describes Sotalol (Sotalex) overdose as a serious, potentially life-threatening event requiring immediate medical attention. The clinical manifestations primarily relate to the drug's beta-blocking and antiarrhythmic effects, which necessitate urgent intervention.

Overdose may present with profound bradycardia (slowed heart rate), severe hypotension (low blood pressure), new or worsened congestive heart failure, and bronchospasm. The most critical cardiac risk is the development of Torsade de Pointes ( TdP), a dangerous form of ventricular arrhythmia, and cardiac asystole.

In all cases of suspected overdose, the official guidance mandates the immediate discontinuation of Sotalex and requires patients to seek emergency medical attention for continuous observation. Because severe cardiac toxicity may have a delayed onset, prolonged hospital monitoring is required. The regulatory information states that no specific antidote is known for Sotalol. Treatment is symptomatic and supportive, utilizing measures such as intravenous fluids, glucagon, and procedures like hemodialysis to manage toxicity and reduce drug concentration. Population-specific risks include a higher likelihood of hypoglycemia (low blood sugar) in children and increased drug accumulation in patients with impaired renal function.

Therapeutic Uses of Sotalex

What Sotalex Treats: Main Uses and Benefits

Sotalex is a prescription-only medication used for managing specific cardiac conditions that require professional oversight. The medication is applied across therapeutic contexts involving significant heart rhythm abnormalities. Its use is relevant for managing documented ventricular arrhythmias and for supporting normal heart rhythm to address the recurrence of highly symptomatic Atrial Fibrillation/Atrial Flutter (AFib/AFL) in appropriate patient groups.

Managing Documented Arrhythmia Patterns

This medicine is commonly used in conditions characterized by periods of heightened symptoms, specifically when the heart's rhythm is excessively fast or irregular. Clinical scenarios often involve the long-term support for rhythm control, especially in patients presenting with conditions such as ventricular tachycardia, ventricular fibrillation, and atrial fibrillation/flutter. It is applied across domains where additional symptomatic support is needed in situations involving recurrent or episodic manifestations. The primary therapeutic benefit is to help support a more stable heart rhythm, which is relevant for easing challenging symptoms.

Easing Symptom Clusters that Interfere with Comfort

Sotalex is relevant for managing symptoms that interfere with daily comfort, such as frequent and uncomfortable palpitations (a fluttering or pounding sensation). Furthermore, the medication helps alleviate systemic distress—symptoms like dizziness, lightheadedness, and fatigue—that are linked to heart rhythm abnormalities. It provides support that helps ease the overall symptom burden, assisting with maintaining functional stability and contributing to improved comfort during periods of heightened symptoms.

“Supports the patient during episodes of heightened discomfort by easing the overall symptom load and assisting with maintaining functional stability.”


Quick Fact: Relief for Palpitations
Sotalex is commonly used to help manage frequent and disruptive palpitations, which are symptoms related to organ-specific functional stress.

Eligibility and Restrictions for Use

Who Can and Cannot Use Sotalex

The eligibility for Sotalex (Sotalol hydrochloride) is strictly determined by official regulatory criteria, primarily based on the patient's existing cardiac function and renal health. The medicine is indicated for use in adult patients without any of the absolute contraindications listed below.

Category Regulatory Status
Absolute Contraindications Use is forbidden in patients with a baseline QTc interval greater than 450 ms, Long QT Syndrome, Sinus Bradycardia (<50 bpm), Second- or Third-Degree AV Block (without a pacemaker), Cardiogenic Shock, or severe Heart Failure (Decompensated) [FDA/EMA].
Renal Eligibility The medicine is contraindicated if the calculated creatinine clearance (CrCl) is less than 40 mL/min. Patients with moderate impairment (CrCl 40 to 60 mL/min) are eligible but require adjusted frequency.
Comorbidities Contraindicated in Bronchial Asthma. Use is restricted in patients with Diabetes Mellitus or Hyperthyroidism because the drug may mask signs of hypoglycemia or thyrotoxicosis.
Age Groups Safety and effectiveness are not established in the general pediatric population. Older adults are eligible but often require dose adjustment due to decreased renal function.
Pregnancy/Lactation Pregnancy is a restricted use category, advised only if the benefit outweighs the risk to the fetus. Use is not recommended during lactation because the substance is excreted into human milk.

Official Eligibility Statements:

  • Sotalex is contraindicated in patients with a creatinine clearance less than 40 mL/min.
  • The medicine must not be used in patients with an acquired or congenital Long QT Syndrome.
  • Use is not recommended during lactation due to its known excretion into human milk.

Connection to the overall eligibility profile:

Regulatory documents define eligibility by establishing absolute prohibitions based on heart conduction, QTc interval, and renal function. The profile strictly mandates that use is reserved for patients who meet these physiological and clinical standards, and only under the restricted conditions documented for specific comorbidities or life stages.

What should I know about interactions with other medicines?

Sotalex’s interaction profile, documented by regulatory authorities, centers on the risk of additive cardiac effects and issues related to drug exposure.

Contraindicated Combinations

Co-administration is formally prohibited with Class I (e.g., Quinidine, Procainamide, Disopyramide) and other Class III antiarrhythmics (e.g., Amiodarone) due to the heightened, potentially fatal, risk of proarrhythmia, specifically Torsade de Pointes (TdP). This prohibition extends to other specific QT prolonging drugs (e.g., Pimozide, Dronedarone, Thioridazine) for the same reason. Floctafenine is also a contraindicated agent [EMA/FDA].

Clinically Significant Interactions

Interactions involving Pharmacodynamic Reinforcement are documented with:

  • Calcium Channel Blockers (Verapamil, Diltiazem): Additive effects on heart rate, blood pressure, and AV conduction, increasing the risk of severe bradycardia and hypotension.
  • Catecholamine-Depleting Agents (e.g., Reserpine): May cause an excessive reduction of sympathetic nervous tone, risking marked hypotension and bradycardia.
  • Antidiabetic Agents: Sotalex may mask key symptoms of acute hypoglycemia, such as tachycardia.
  • Potassium-Depleting Agents (e.g., Loop/Thiazide Diuretics): These substances can cause hypokalaemia, which significantly exaggerates the risk of TdP.

Administration Requirements

The regulatory label includes specific timing rules to manage absorption interference:

  • Antacids (containing Aluminum or Magnesium Hydroxide): Must be administered at least two hours before or two hours after Sotalex to minimize reduced Sotalol absorption.
  • Food: Sotalex should be taken one to two hours before meals as absorption is reduced when taken with food.

Mechanism of Action

The mechanism of action for Sotalex involves a dual-action pharmacodynamic profile, combining Class II and Class III antiarrhythmic properties on cardiac tissue.

Non-Selective beta-Adrenergic Receptor Blockade

The primary Class II activity is the non-selective antagonism of beta1 and beta2 adrenergic receptors. This receptor blockade modulates sympathetic signaling at the myocardium, a process associated with a reduction in the rate of impulse generation (negative chronotropy) and a decrease in the force of myocardial contraction (negative inotropy).

Inhibition of the Delayed Rectifier Potassium Current (IKr)

The distinct Class III effect is achieved by selectively blocking the delayed rectifier potassium current (IKr) in cardiac myocytes. This ionic current inhibition decreases the repolarizing efflux of potassium ions, which in turn prolongs the duration of the action potential and increases the effective refractory period in both atrial and ventricular tissues. The combined dual action modifies the electrophysiological properties of the myocardium.

Dosage and Administration Information

How to Use Sotalex

Sotalex (sotalol hydrochloride) is administered as oral tablets for chronic use or as an intravenous injection for monitored or acute settings. Its use follows a strict protocol.


Administration Guidelines

Element Instruction
Route of Administration Oral tablets or intravenous (IV) injection.
Dosing Schedule (Adults) Initial dose is typically 80 mg twice daily (BID). The dose is increased in 80 mg/day increments, waiting at least three days between adjustments.
Frequency Adjustment Dosing interval is extended based on Creatinine Clearance (CrCl). For CrCl 30-59 mL/min, the dose or frequency is reduced.
Special Condition Therapy initiation and any dose increase must occur in a specialized hospital facility that can provide continuous cardiac monitoring for a minimum of three days.
Discontinuation Long-term therapy should be discontinued gradually over a period of one to two weeks.

Resulting Procedural Structure

The protocol mandates calculating the patient's renal function (CrCl) prior to initiation to determine the correct dosing frequency. The initial oral dose of 80 mg BID serves as the starting point, followed by a controlled titration process with a minimum three-day waiting period between adjustments. The maximum total daily dose for most patients is 320 mg, though higher doses are used for refractory conditions. If a dose is missed, the next dose should not be doubled.

Recent Clinical Evidence

Research evidence / Overview of studies for Sotalex


Evidence for Heart Rhythm Control in Life-Threatening Ventricular Arrhythmias

The evidence base for Sotalex includes studies focused on serious ventricular arrhythmias—such as life-threatening ventricular tachycardia—and relies on Randomized Controlled Trials (RCTs) and large comparative trials. Researchers applied these studies to evaluate whether the medicine could help suppress or prevent the recurrence of these heart rhythm problems. The main outcomes monitored included the rate at which the fast, irregular rhythms returned over time and the overall survival rates for the observed populations.

Studies focusing on these high-risk patients have described patterns where the medicine was observed to maintain a normal heart rhythm for a longer duration compared to placebo in some settings. Research monitored specific changes in the heart's electrical properties. However, observations in these populations did not consistently describe a difference in long-term overall survival when compared to the control group. Research has explored the medicine's potential role in preventing recurrence, but evidence has not clearly established a difference in how long patients lived overall in the populations studied.

Evidence for Maintaining Normal Rhythm in Atrial Fibrillation/Flutter (AFib/AFL)

For studies related to long-term rhythm control in Atrial Fibrillation or Atrial Flutter (AFib/AFL), research has concentrated on the medicine’s ability to help patients stay in a normal heart rhythm after a successful conversion. The primary evidence comes from double-blind, multicenter RCTs that compared Sotalex to a placebo or to other antiarrhythmic medications. Researchers measured the crucial outcome of the time to the first symptomatic, documented recurrence of AFib or AFL.

In these trials, studies reported that patients taking the study medicine experienced a longer time interval before the documented recurrence of AFib/AFL compared to those receiving placebo. Studies also reported specific rates at which symptomatic AFib/AFL recurred over the typical follow-up periods of 6 to 12 months. These studies provide context by monitoring how symptoms evolved in the observed populations.


Research Gaps and Areas of Uncertainty

Overall Survival: Studies examining life-threatening ventricular arrhythmias have not consistently described a difference in long-term overall survival, and this outcome remains an area of uncertainty in the evidence landscape.

Subgroup Heterogeneity: Research has not fully established findings for all specific high-risk patient subgroups, such as those with certain severe structural heart diseases. Results apply only to the populations studied in the trials, and comparative evidence against all modern therapies is still emerging.

Special Populations: The evidence for non-AF supraventricular tachycardias (SVT) and its use in pediatric cohorts relies mainly on smaller cohort studies and registries, resulting in variability in reported observations compared to the larger RCTs for AFib and ventricular arrhythmias.

Frequently Asked Questions (FAQ)

Common questions about Sotalex (FAQ)


Q: How long does it typically take for Sotalex to reach its full effect?

A: According to official product information, achieving the medicine’s full therapeutic effect is a gradual process. The dosing is managed through a controlled titration process, which includes a minimum waiting period between dose adjustments. This is necessary to allow the drug to reach stable levels (steady-state concentrations) in the body before its effectiveness is assessed.

Q: Is Sotalex generally prescribed for long-term use?

A: Regulatory documents indicate that Sotalex is used for the long-term maintenance of normal heart rhythm, particularly in patients with symptomatic Atrial Fibrillation or Atrial Flutter. This therapeutic goal suggests that the medicine is generally intended for chronic use.

Q: Does Sotalex commonly cause stomach issues like nausea or diarrhea?

A: Official information indicates that common adverse reactions affecting the digestive system (1% to 10% frequency) include nausea, vomiting, and diarrhea. Any concerning symptoms observed should be discussed with a healthcare professional.

Q: What is the difference between Sotalex and other anti-arrhythmic medicines like Amiodarone?

A: Sotalex is classified as a Class II and Class III anti-arrhythmic. Official regulatory documents strictly prohibit the co-administration of Sotalex with other Class I and Class III anti-arrhythmics, such as Amiodarone, due to a significantly heightened risk of proarrhythmia.

Q: Are there any known interactions between Sotalex and alcohol consumption?

A: Official consumer information advises that combining Sotalex with alcohol may lead to an additive effect in lowering blood pressure. This could potentially result in increased dizziness, drowsiness, or an abnormally low blood pressure.

Q: Does Sotalex have an effect on blood pressure?

A: Yes, Sotalex belongs to a class of drugs that are known to produce significant reductions in both systolic and diastolic blood pressures. The official label notes that this effect may result in hypotension, which is low blood pressure.

Q: What are the signs of a possible allergic reaction to Sotalex?

A: While anaphylaxis is listed as a serious adverse reaction, general signs of an allergic reaction may include difficulty breathing, wheezing, or swelling of the face, lips, or tongue. Skin reactions such as a rash or itching may also occur. Any concerning symptoms observed should be discussed with a healthcare professional.

Q: Does Sotalex have potential interactions with common over-the-counter pain relievers or cold medicines?

A: The official label lists specific warnings for many classes of prescription drugs. However, it does not provide a blanket statement on all over-the-counter pain relievers or cold medicines. A review of all active ingredients with a healthcare professional is recommended.

Q: Is there any information available about Sotalex causing hair loss or thinning?

A: Official reports based on clinical experience indicate that hair loss or thinning of the hair is reported as a rare adverse reaction to Sotalex.

Q: Can Sotalex affect a person's sleep quality or cause insomnia?

A: Yes, difficulty with sleeping, often referred to as a sleep problem or insomnia, is listed as a common side effect of Sotalex in official adverse reaction tables.

Q: Are there any general restrictions on physical activity or strenuous exercise while taking Sotalex?

A: Regulatory documents do not generally restrict physical activity. The official label, however, contains strict warnings against abruptly stopping the medication due to the risk of serious adverse cardiac events.

Q: Does Sotalex have an impact on sexual function or desire?

A: Official adverse reaction reports indicate that decreased sexual performance or desire is reported as a less common side effect associated with the use of Sotalex.

Q: What are the reported frequencies of less common side effects like headache or blurred vision with Sotalex?

A: Both headache and vision problems (which can include blurred vision) are listed as common side effects, occurring in 1% to 10% of patients observed in clinical trials. The frequency of side effects is usually dose-related.

Q: Does the use of Sotalex require regular blood tests to check for certain markers?

A: Official warnings state that patients require monitoring of serum potassium and magnesium levels before starting therapy. Furthermore, special attention to electrolyte balance is necessary during treatment, particularly if a patient experiences severe diarrhea or is taking diuretics.

Q: Are mood changes or depression considered a possible side effect of Sotalex?

A: Yes, mood change and depression are reported as common psychiatric adverse reactions in the official product information, occurring in 1% to 10% of patients.

Q: Is it generally necessary to inform a surgeon or dentist that one is taking Sotalex before a procedure?

A: A warning in the official label advises that the prescriber should be informed if a patient is scheduled for major surgery. This is due to the risk of severe low blood pressure and the difficulty of restoring a normal heart rhythm during a procedure.

Q: Can Sotalex cause weight gain or weight changes?

A: Yes, weight change (gain or loss) is reported as a common metabolic adverse reaction, occurring in 1% to 10% of patients in clinical trials.

Q: Why is Sotalex sometimes given as an intravenous (IV) infusion?

A: The IV injection route is used for administration in acute settings or for the initiation of therapy in monitored facilities. This method is used when immediate therapeutic levels are needed alongside continuous clinical observation.

Q: Is Sotalex generally well-tolerated by most patients?

A: Official clinical trial data provides context on tolerability. For instance, in trials for Atrial Fibrillation/Flutter, 17% of patients discontinued treatment due to adverse events, which included fatigue, bradycardia, or proarrhythmia.

Q: What is the typical appearance of a Sotalex tablet (color, shape, marking)?

A: The appearance of the tablet can vary based on the specific dose and manufacturer. For example, some regulatory labels describe the 80 mg tablet as a light-blue, capsule-shaped tablet for oral administration.

Q: Are there specific lifestyle changes that may be recommended while on Sotalex?

A: The official label contains warnings that the medicine may mask the signs of low blood sugar. This warning implies that patients with diabetes may need to be particularly vigilant in monitoring their blood sugar levels while using the medicine.

Q: Can Sotalex cause a skin rash or itching?

A: Yes, a skin rash is reported as a common adverse reaction (1% to 10% frequency) in the official product information. Itching skin (pruritus) is also reported, though this is listed as a rare adverse reaction.

Q: Is Sotalex a drug that is eliminated primarily through the kidneys?

A: Yes, Sotalol is primarily removed from the body through the renal route, meaning the kidneys. This fact is the reason why dosage adjustments are often necessary for patients who have kidney problems.

Q: What are the key differences between Sotalex AF and regular Sotalex?

A: Official product information shows that the AF formulation is specifically indicated for maintaining a normal sinus rhythm in patients with symptomatic Atrial Fibrillation or Atrial Flutter. The standard product is also indicated for life-threatening ventricular arrhythmias.

Q: What happens to the body's response to epinephrine (adrenaline) while taking Sotalex?

A: Due to Sotalol’s action as a beta-blocker, its presence may counteract or limit the body’s response to adrenergic stimulants, such as epinephrine. This effect is relevant to the management of allergic reactions or during certain medical procedures.

Q: How quickly does the effect of Sotalex wear off after stopping use?

A: The elimination half-life of Sotalex is approximately 12 hours. This measurement indicates the time it takes for the concentration of the drug in the blood to decrease by half after administration is stopped.

How should Sotalex be stored and disposed of?

How to Store and Dispose of Sotalex?

Sotalex (sotalol hydrochloride) tablets must be stored according to specific regulatory conditions to maintain their stability.


Storage Requirements

Condition Requirement
Temperature Store at Controlled Room Temperature, defined as 15 C to 30 C (59 F to 86 F).
Environment Keep the container tightly closed in a dry place and away from excessive heat and freezing.
Protection Store in a light-resistant container and out of the reach of children.

Disposal Instructions

Disposal must adhere to official protocols for pharmaceutical waste. Do not dispose of unused or expired Sotalex with household garbage or by flushing it into the sewers or surface water. The medicine should be disposed of in accordance with local/national regulations, often requiring disposal at an approved waste collection point or facility, as advised by a healthcare professional.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Sotalex found in:

A-Z Index: